Pharmanutra Logo

Pharmanutra

Researches and markets nutritional supplements & medical devices for all ages.

PHN | XMIL

Overview

Corporate Details

ISIN(s):
IT0005274094
LEI:
815600F8217BC7733697
Country:
Italy
Address:
VIA CAMPODAVELA, 1, 56122 PISA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 2003, PharmaNutra is a company specializing in the research, development, and marketing of nutritional supplements and medical devices. The firm emphasizes scientific innovation and manages the entire production process, from proprietary raw materials to finished goods. Through its in-house research centers and labs, it pioneers studies to create unique and effective products. The portfolio focuses on addressing nutritional deficiencies, such as minerals and vitamins, and supporting musculoskeletal and joint health for consumers of all ages.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 08:50
Regulatory News Service
Italian Roadshow 2025 - Paris
Italian 5.4 MB
2025-11-14 10:19
Regulatory News Service
INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2025
Italian 1.7 MB
2025-11-14 10:17
Regulatory News Service
Resoconto intermedio di gestione al 30 settembre 2025
Italian 1.7 MB
2025-11-13 09:58
Regulatory News Service
Interim Management report as at September 30 2025
Italian 1.8 MB
2025-11-13 09:56
Regulatory News Service
Resoconto Intermedio di gestione al 30 settembre 2025
Italian 1.7 MB
2025-11-13 09:54
Regulatory News Service
Avviso deposito Rendiconto Intermedio di gestione al 30 settembre 2025 || Notic…
Italian 225.3 KB
2025-11-10 17:51
Earnings Release
PHARMANUTRA S.P.A.: BOARD OF DIRECTORS APPROVES THE INTERIM MANANGEMENT REPORT …
English 338.9 KB
2025-11-10 17:49
Earnings Release
PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTE…
Italian 342.0 KB
2025-11-04 11:34
Director's Dealing
ALLEGATO 3F - OTTOBRE 2025
Italian 93.2 KB
2025-10-20 08:00
Regulatory News Service
“SIDERAL® FORTE” PREMIATO COME MIGLIOR PRODOTTO NUTRACEUTICO || “SIDERAL® FORTE…
Italian 278.3 KB
2025-10-03 13:13
Transaction in Own Shares
Initiation of share buy-back program
English 243.9 KB
2025-10-03 13:12
Transaction in Own Shares
Avvio del programma di acquisti di azioni proprie
Italian 232.8 KB
2025-10-01 09:00
Investor Presentation
Eccellenze del Made in Italy | Presentazione
English 5.0 MB
2025-09-12 10:35
Interim Report
Half Year Financial Report 2025
English 3.3 MB
2025-09-12 10:34
Interim Report
Relazione finanziaria semestrale 2025
Italian 3.4 MB

Automate Your Workflow. Get a real-time feed of all Pharmanutra filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pharmanutra

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pharmanutra via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Developing protein degradation medicines to treat cancer and autoimmune diseases.
United States of America
NRIX
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nxera Pharma Co., Ltd. Logo
Biopharma using SBDD tech to develop medicines for neurology and gastroenterology.
Japan
4565
ObsEva SA Logo
Developed novel therapeutics for women's reproductive health and pregnancy.
Switzerland
OBSN
OCULAR THERAPEUTIX, INC Logo
Develops hydrogel drug delivery therapies for eye diseases like wet AMD and glaucoma.
United States of America
OCUL

Talk to a Data Expert

Have a question? We'll get back to you promptly.